Aurobindo Pharma has inked a collaboration and license agreement with a major global pharmaceutical company to develop and commercialise specific products within the respiratory therapeutic area. This agreement is expected to span an estimated initial development period of three to five years.

During this time, both companies will collaborate on the development of the targeted products. The arrangement specifies that both companies will co-exclusively commercialise the products, covering joint handling of marketing and sales efforts once the products are commercialised.

The manufacturing of these products will take place at the partner’s facility, ensuring a streamlined production process. Aurobindo Pharma also holds the option to transfer technology at a later stage, which could allow for further integration or expansion of the collaboration in the future.

This partnership aims to share the development costs, reducing the overall time and effort required to bring the products to market. By working together, the companies hope to reduce the gestation period typically associated with developing new products from scratch. The joint effort allows both parties to leverage each other’s capabilities, maximising the chances of successful product development.